Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + zimberelimab plus chemotherapy versus nivolumab plus chemotherapy for first-line unresectable or metastatic upper gastrointestinal adenocarcinoma
MOH_2023-04-30_012590Phase 3Recruiting
- Sponsor
- Arcus Biosciences
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of domvanalimab and zimberelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 1 more (2 arms), sponsored by Arcus Biosciences. Primary endpoint: Overall survival. Started Mar 2023; status: recruiting.
02
Drugs
domvanalimabzimberelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)upper gastrointestinal adenocarcinoma
Beyond the preview
Go deeper on MOH_2023-04-30_012590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-30_012590.